Study and Role of Inflammasome in Platelet Activation During Bacterial And/or Viral Sepsis

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

: Sepsis, now defined as life-threatening organ dysfunction due to a dysregulated host response to infection, is an important global health problem representing about a fifth of all global deaths. It can be associated, in some cases, with multiple organ failure and cytokine storm. The main objective of this study is to estimate and to compare the activation rate of the Nucleotide-binding domain Leucine Rich repeat containing Protein 3 (NLRP3) inflammasome in platelets between five groups of patients suffering from bacterial and/or viral sepsis, with different severity levels according to Sequential Organ Failure Assessment (SOFA) score to precise the platelets' implication in this cytokine storm.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:

• For all groups: patients older than 18 years at inclusion and acceptation of participation by the patient, his relative or his legal representative (depending on the situation)

• For groups 1, 2, 3 and 5: Patient with a confirmed sepsis (microbiological confirmation)

• For group 4 : Patient non infected

Locations
Other Locations
Guadeloupe
Centre Hospitalier Universitaire de la Guadeloup
RECRUITING
Les Abymes
Contact Information
Primary
Frédéric MARTINO, Doctor
frederic.martino@chu-guadeloupe.fr
+590 590 89 10 10
Time Frame
Start Date: 2022-11-30
Estimated Completion Date: 2026-11
Participants
Target number of participants: 171
Treatments
leptospirosis
patient suffering from leptospirosis
bacterial
patient suffering from bacterial infections including in-hospital-acquired-infections
viral
patient suffering from viral infection except COVID-19
Control
patients non infected
viral infection SARS-COv2 +
patient suffering from COVID-19 previously enrolled in PLAQCOVID trial.
Related Therapeutic Areas
Sponsors
Leads: Centre Hospitalier Universitaire de la Guadeloupe

This content was sourced from clinicaltrials.gov